Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Peak Bio, Inc.

P-BIO is a private non-profit association that brings together companies linked to the biotechnology and life sciences sector in Portugal.

P-BIO

Peak Bio, Inc. develops innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer.

Peak Bio Inc. | 789 followers on LinkedIn. Clinical-stage biopharmaceutical company. #PKBO | Our goal is to find innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer.

Notice to recruiters

All recruitment vendors (temporary staffing agencies, placement services, and professional recruiters) are prohibited from contacting our employees.

In order to be an authorized vendor partner for Peak Bio, all such organizations must have a formal written agreement with Peak Bio’s Human Resources Department. 

pH Pharma Inc. Director

신용남

Metric
Company Name	Peak Bio, Inc.	P-BIO
Symbol	PKBO
MSH ID	COM:PEAK-BIO	ORG:P-BIO
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	PT
Stage
Employee Count	21
Website	peak-bio.com	p-bio.org
LinkedIn	peakbioinc	p-bio
Founders

Metric
Market Cap	192.60K
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	367.88K
Revenue (LTM)
Revenue (NTM)
Gross Profit	367.77K
EBITDA
Operating Income
Net Income	-1.26K
EPS	-0.01
Diluted EPS	-0.01
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1.00
Operating Profit Margin	-16.52
EBITDA Margin	-0.00
Net Profit Margin	-13.07
Return on Equity	1.83
Return on Assets	-3.23
Return on Capital Employed	1.26

COM:PEAK-BIO

Peak Bio, Inc.

Last Close

0.05

14/11 20:00

Market Cap

192.60K

Beta: -

Volume Today

1.93K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.03
P/B Ratio	-0.04
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	11.76
EV Multiple	1.84

Metric
Days Sales Outstanding
Days Payables Outstanding	532.66
Days Inventory Outstanding
Operating Cycle	371.35
Cash Conversion Cycle	-178.20
Asset Turnover	47.76

Metric
Operating Cash Flow	-4.76M
Free Cash Flow	-4.76M
Cash Flow to Debt
Operating Cash Flow/Sales	-9.37
Free Cash Flow Yield	-9.31

Metric
Cash & Equivalents	381.65K
Accounts Receivable	-68.16
Inventory
Goodwill
Debt to Capitalization	1.00
Debt to Assets	4.23
Current Ratio	0.08
Quick Ratio	114.86

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.48
R&D to Revenue	6.31M
SG&A to Revenue	20.28